Home > Resources > Whitepapers > An update on Regulatory Scenario in India

An update on Regulatory Scenario in India

India being one of the most populated countries with 1.3 billion people and a premier emerging economy is a key market for multinational pharmaceutical and biotech companies to launch their drug products. As a growing market, innovator drug and biotech companies are required by the drug regulatory authority of India to conduct clinical studies involving the local population to prove safety and efficacy of the drug product.

Spotlight

Medical Innovations Group

Medical Innovations Group designs and manufactures medical equipment for a diverse range of markets - from Hospitals and Emergency Services to the Armed Forces. All products are developed under tight quality-controlled conditions and have undergone extensive testing and trials. As a result, they meet the highest possible quality and regulatory standards.

OTHER WHITEPAPERS

70 years of wood modifcation with fungi

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites